Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study.
Ryohei KawabataKeisho ChinDaisuke TakahariHisashi HosakaOsamu MutoYoshiaki ShindoNaoki NagataHiroshi YabusakiHiroshi ImamuraShunji EndoTomomi KashiwadaMasato NakamuraJun HiharaMichiya KobayashiTamotsu SagawaSoh SaitoAtsushi SatoTakeshi YamadaNaohiro OkanoKen ShimadaMasashi MatsushimaMasato KataokaShigemi MatsumotoMasahiro GotoMasahito KotakaTakeshi ShiraishiHiromichi YamaiFumio NagashimaNaoki IshizukaKensei YamaguchiPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2023)
These findings demonstrate CapeOX's efficacy and safety in older AGC patients.
Keyphrases
- phase ii study
- end stage renal disease
- locally advanced
- open label
- newly diagnosed
- physical activity
- chronic kidney disease
- community dwelling
- middle aged
- peritoneal dialysis
- palliative care
- prognostic factors
- randomized controlled trial
- squamous cell carcinoma
- rectal cancer
- placebo controlled
- phase iii
- patient reported